Erytech Pharma (NASDAQ:ERYP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, reports. The firm currently has a $9.50 price target on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.56% from the stock’s previous close.

According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “

Shares of NASDAQ ERYP traded down $0.47 during mid-day trading on Tuesday, reaching $8.44. The company had a trading volume of 500 shares, compared to its average volume of 3,749. The business’s 50-day moving average is $8.89 and its 200-day moving average is $6.87. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 0.15. The stock has a market cap of $159.85 million, a price-to-earnings ratio of -2.15 and a beta of 2.54. Erytech Pharma has a 52 week low of $3.50 and a 52 week high of $12.00.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

Read More: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with's FREE daily email newsletter.